Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (not Quoin Pharmaceuticals, Ltd.) on June 26, 2017. The filing serves as a report of a foreign private issuer under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document incorporates by reference a notice titled "Update on the Announcement on Moving to Exclusive Trading on the NASDAQ."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding trading venue changes and does not contain financial statements or performance data.
Material Changes
The primary material event disclosed is the company's update regarding its transition to exclusive trading on the NASDAQ. No financial comparisons to prior periods are included in this specific filing.
Guidance, Outlook, and Risks
Management commentary is limited to the procedural update on the NASDAQ trading migration. The filing does not contain forward-looking guidance, risk factors, contingencies, or discussions of unusual items beyond the trading venue change.
Key Facts for Investor Verification
- Verify the current trading status of Cellect Biotechnology Ltd. shares on the NASDAQ.
- Confirm the exact date the transition to exclusive NASDAQ trading was completed.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F for financial metrics.
- Ensure the registrant name is correctly identified as Cellect Biotechnology Ltd., not Quoin Pharmaceuticals, Ltd.